Alpha Adrenergic Receptor Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Alpha Adrenergic Receptor Antagonists Market size was valued at USD XX Mn in 2023 and is expected to grow at XX% CAGR over the forecast year 2024 – 2030. Alpha-adrenergic receptors are a class of adrenergic receptors that belong to the larger family of G protein-coupled receptors (GPCRs). These receptors are activated by neurotransmitters and hormones called catecholamines, such as norepinephrine (noradrenaline) and epinephrine (adrenaline). Alpha-adrenergic receptors play a crucial role in regulating various physiological responses in the body, including smooth muscle contraction, blood vessel constriction, and heart rate. There are two main subtypes of alpha-adrenergic receptors: alpha-1 and alpha-2. Each subtype has multiple subcategories. Alpha-adrenergic receptor antagonists, also known as alpha-blockers, are a class of drugs that block the activity of alpha-adrenergic receptors. By doing so, they interfere with the binding of norepinephrine and other catecholamines to these receptors, resulting in various physiological effects such as vascular smooth muscle relaxation, relief of urinary symptoms, and enhanced release of neurotransmitters.

Alpha Adrenergic Receptor Antagonists have been identified as an effective therapeutic strategy for CNS disorders, bipolar disorders, mood disorders, acute coronary syndrome, psychomotor agitation, schizophrenia, and stress disorders to name a few. Increased prevalence of CNS disorders like schizophrenia and depression are the key drivers for the Alpha Adrenergic Receptor Antagonists market. For instance, according to the World Health Organization, Depression is one of the most prevalent mental health conditions globally, and estimated that more than 264 million people worldwide were affected by depression in 2020. Moreover, to overcome difficulties in therapy, various market players are developing innovative compounds. For instance, Integrative Research Laboratories molecule Pirepemat (IRL752) for the indication of Parkinson's disease is under the various stages of clinical studies.

Key Market Developments:

In April 2023, FDA confirmed the filing of Minerva Neurosciences NDA for Roluperidone for the treatment of negative symptoms in patients with schizophrenia.

 Drugs under the Pipeline for Alpha Adrenergic Receptor Antagonists:

• Roluperidone (MIN-101)
• Lodopin (Zotepine)
• Pirepemat (IRL752)
• Secuado (Asenapine Transdermal)

Clinical Activity and Developments of Alpha Adrenergic Receptor Antagonists:

Till July 2023, more than 4 companies have approximately 10 molecules targetting a number of CNS diseases. For these molecules, more than 25 clinical trials are being conducted and the majority are in phase-1, phase-2 clinical trials by players across the globe. For instance,

• In November 2018, Integrative Research Laboratories completed phase 2, a randomized, double-blind, placebo-controlled, multi-center phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's disease dementia.
• In December 2022, Minerva Neurosciences completed phase 3, a multicenter, randomized, double-blind, parallel-group, placebo-controlled, monotherapy, 12-week study to evaluate the efficacy and safety of 2 fixed doses of MIN-101 in adult patients with negative symptoms of schizophrenia, followed by 40-week open-label extension.